Top NYC, NY Biotech Companies (116)
Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, Click delivers accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Click’s treatments are defined by a commitment to applying technical and scientific rigor and patient-centric design to the development process. This results in uniquely engaging experiences that achieve compelling clinical outcomes for patients seeking new treatment options. Click Therapeutics continuously expands and refines its platform with novel cognitive, behavioral and neuromodulatory mechanisms of action and advanced data-driven tools such as artificial intelligence and machine learning. The digital therapeutics under development on Click’s platform address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases. Consistently named a best place to work, Click fosters an inclusive, diverse workforce of innovators, clinicians, scientists, researchers, designers, technologists, engineers and more, united in a common mission to provide patients everywhere access to safe and effective prescription digital therapeutics. For more information, visit www.clicktherapeutics.com and connect with us on LinkedIn. NOTE: Fake job advertisements and offers are increasingly appearing on the internet. If you have encountered a job posting or have been approached with a job offer that you suspect may be fraudulent, we strongly recommend you do not respond and report it to the Federal Trade Commission and to [email protected]. Other than your email address or telephone number, which you may provide via a job application portal, Click Therapeutics will never ask you to provide personally identifiable information about yourself (such as a Social Security Number or Driver’s License Number) via a messaging application.
At Inato, we’re on a mission to accelerate the pace of medical innovation by bringing clinical research to each and every patient, regardless of who they are and where they live. Our platform, made to connect community-based research centers to trials across the globe, aims to create greater visibility, access, and engagement across a more diverse population of doctors and their patients.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture. Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater value per program and accelerating access to new treatments for patients. Join our culture of innovation where your work directly contributes to transforming patient care in areas such as rheumatology, dermatology, CNS, and cardiometabolic diseases. Our dynamic environment blends advanced technology with strategic drug development, speeding up the delivery of new treatments. Here, every role plays a part in our mission to bring new treatments to patients faster and more efficiently.
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for pro-innovation/pro-patient policies.
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
We are a digital-first, life sciences commercialization company. We help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. We bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions. These aim to deliver, amongst other outcomes, a personalized, scalable and omnichannel experience for patients and physicians. It’s what drives our team and our purpose to enable healthcare organizations to be future ready.
Output Biosciences is the world’s first preventative therapeutics company that extends human healthspan by combating chronic disease.
We are building a synthetic alternative to cell therapies—a tunable, cell-free system that mimics regenerative signaling with precision across indications. Our first candidate targets Osteoarthritis.
The mission of The New York Stem Cell Foundation is to cure the major diseases of our time through stem cell research. In addition to conducting innovative stem cell research in our own safe haven laboratories, NYSCF also supports and convenes global stem cell thought leaders and the broader stem cell community – all with the focus on getting to patients. Since our founding in 2005, NYSCF has been able to achieve outsized results in a relatively short period of time thanks to private philanthropy. The NYSCF Research Institute, an independent laboratory, is a non-profit accelerator that serves to bridge the ongoing gap between research institutions and pharmaceutical and biotech companies by reducing the cost, time, and risk that historically inhibit the development of new treatments and cures. In just over one decade, NYSCF has created not only foundational tools for using stem cells in basic research, but also pioneering technologies that will allow stem cells to be used therapeutically. By pursuing and supporting only the most promising stem cell research and technologies, in our own laboratories and in partnership with leading institutions around the world, NYSCF serves as a catalyst in this transformational field, advancing our mission to accelerate cures for the major diseases of our time
Kinevant Sciences is a clinical-stage biopharmaceutical company dedicated to treating rare autoimmune diseases with significant unmet need. Our lead candidate, namilumab, is an investigational monoclonal antibody being developed for the treatment of sarcoidosis. Namilumab targets GM-CSF, a key pro-inflammatory cytokine and growth factor implicating in the pathogenesis of sarcoidosis and other inflammatory disorders. We plan to initiate a global Phase 2 clinical trial in the first half of 2022 investigating namilumab in pulmonary sarcoidosis, which affects ~90% of all sarcoidosis patients.
We are a biopharmaceutical company that leverages a decentralized platform approach to incubate and accelerate the development of highly effective mental health treatments that address the unmet needs of patients.
Pulse Analytics builds business intelligence tools that help decision-makers in oncology and other specialty therapeutic areas reduce access barriers and restrictions in the healthcare industry. Pharma market access teams utilize our tools to understand the complex connections, policies, and key influencers at healthcare organizations to deliver targeted insights and support their customer engagement strategies. We go above traditional data platforms by operating in a highly specialized space and partnering with industry experts allowing our tools to provide tailored experiences that meet the unique needs and challenges of our clients.
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com. For U.S. residents only.
Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Founded in 2022 by Population Health Partners and ARCH Venture Partners, Metsera has raised $290 million in financing from leading healthcare investors and is based in New York City.
Owkin is a French-American startup that uses artificial intelligence to find the right treatment for every patient. Our focus is to use AI to discover and develop better treatments for unmet medical needs, starting with the fight against cancer. We use AI to identify new drug candidates, de-risk and accelerate clinical trials and build diagnostic solutions that improve patient outcomes. Using federated learning, a pioneering collaborative AI framework, Owkin enables medical and biopharma partners to unlock valuable insights from siloed datasets, while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a clinical research doctor and former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $255 million and became a ‘unicorn’ – a startup valued at more than $1 billion – in November 2021 through a $180 million investment from French biopharma company Sanofi.
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational, intravenous phospholipid substrate replacement therapy in development for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.
Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 300,000 customers from over 160 countries and regions worldwide have used GenScript’s premier, convenient, and reliable products and services. GenScript currently has over 5,000 employees globally, 33% holding master’s and/or Ph.D. degrees. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis, and bioinformatics, including more than 100 patents and over 270 patent applications. As of June 2022, GenScript's products and services have been cited by 74,700 scientific papers worldwide. GenScript is committed to striving toward its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.
AlgiKnit is creating eco-conscious, renewable yarns for the circular economy. We’re developing durable yet rapidly degradable yarns from kelp, one of the most regenerative organisms on the planet. Our material is built for everyone: a functional and accessible resource without environmental harm. We’re envisioning a future where the textile industry operates in a closed-loop product lifecycle, utilizing materials with a significantly lower footprint than conventional textiles.
Work Your Passion. Live Your Purpose.